{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:45:46Z","timestamp":1747205146177,"version":"3.40.5"},"posted":{"date-parts":[[2024,3,14]]},"group-title":"In Review","reference-count":86,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,3,13]]},"abstract":"<title>Abstract<\/title>\n        <p>Racial and ethnic minorities have been disproportionally burdened by hospitalization and death due to COVID-19. Participation of individuals of diverse races and ethnicities in clinical trials according to study-level characteristics of randomized controlled trials (RCT) that test effectiveness of COVID-19 drugs could be insightful for future researchers. The objective of this scoping review was to describe frequency of race and ethnicity reported as demographic variables and specific reporting of race and ethnicity according to COVID-19 RCT characteristics. We conducted comprehensive searches in Pubmed, ProQuest, WHO Database, and Cochrane Central Register of Controlled Trials, and gray literature via preprint servers from 1\/1\/2020 to 5\/4\/2022. We included RCTs on emergency- or conditionally-approved COVID-19 drug interventions (remdesivir, barcitinib, and molnupiravir) with or without comparators. Self-reported race as American Indian\/Pacific Islander, Asian, Black\/African American, or White, ethnicity as Hispanic\/Latinx, study design characteristics, and participant-relevant data were collected. A total of 17 RCTs with 17935 participants was included. Most (n=13, 76%) reported at least one race and ethnicity and were US-based, industry-funded RCTs. Asian, Black, Latinx, and White participants were mostly enrolled in RCTs that studied remdesivir. Native American and Hawaiian participants were mostly assessed for progression to high-flow oxygen\/non-invasive ventilation. Time to recovery was assessed predominantly in Black and White participants, while hospitalization or death was mostly assessed in Asian, Latinx, and multi-race participants. Trialists should be aware of RCT-level factors and characteristics that may be associated with low participation of racial and ethnic minorities, which could inform evidence-based interventions to increase minority participation.\nRegistration: Open Science Framework:  https:\/\/osf.io\/3dx4f\/?view_only=d1af00d952cc472b803df5297bce9a80<\/p>","DOI":"10.21203\/rs.3.rs-4092537\/v1","type":"posted-content","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:32:31Z","timestamp":1710441151000},"source":"Crossref","is-referenced-by-count":0,"title":["Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5524-1723","authenticated-orcid":false,"given":"Shelly Melissa","family":"Prani\u0107","sequence":"first","affiliation":[{"name":"University of Split School of Medicine"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-8363","authenticated-orcid":false,"given":"Maria Dulce","family":"Estev\u00e3o","sequence":"additional","affiliation":[{"name":"Escola Superior de Sa\u00fade da Universidade do Algarve"}]},{"given":"Lenny T.","family":"Vasanthan","sequence":"additional","affiliation":[{"name":"Christian Medical College"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-7272","authenticated-orcid":false,"given":"Iv\u00e1n","family":"P\u00e9rez-Neri","sequence":"additional","affiliation":[{"name":"National Institute of Neurology and Neurosurgery"}]},{"given":"Anika","family":"Pulumati","sequence":"additional","affiliation":[{"name":"University of Missouri-Kansas City School of Medicine"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-8775","authenticated-orcid":false,"given":"F\u00e1bio Antonio Serra de Lima","family":"Junior","sequence":"additional","affiliation":[{"name":"Universidade Federal da Para\u00edba (Federal University of Para\u00edba)"}]},{"given":"Narges","family":"Malih","sequence":"additional","affiliation":[{"name":"Global Health Research Group"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-0340","authenticated-orcid":false,"given":"Vinayak","family":"Mishra","sequence":"additional","affiliation":[{"name":"University of Liverpool"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9775-361X","authenticated-orcid":false,"given":"Jacqueline","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Birmingham"}]},{"given":"Daniel","family":"Nnate","sequence":"additional","affiliation":[{"name":"University of Liverpool"}]}],"member":"297","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M20-6306","article-title":"Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: A systematic review","volume":"174","author":"Mackey K","year":"2021","unstructured":"Mackey K, Ayers CK, Kondo KK et al (2021) Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: A systematic review. Ann Intern Med 174(3):362\u2013373. doi.org\/10.7326\/M20-6306","journal-title":"Ann Intern Med"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.18865\/ed.32.1.31","article-title":"The relationship between systemic racism, residential segregation, and racial\/ethnic disparities in COVID-19 deaths in the United States","volume":"32","author":"Franz B","year":"2022","unstructured":"Franz B, Parker B, Milner A et al (2022) The relationship between systemic racism, residential segregation, and racial\/ethnic disparities in COVID-19 deaths in the United States. Ethn Dis 32(1):31\u201338. 10.18865\/ed.32.1.31","journal-title":"Ethn Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.jmh.2021.100041","article-title":"Clinical outcomes and risk factors for COVID-19 among migrant populations in high-income countries: A systematic review (electronic article)","volume":"3","author":"Hayward SE","year":"2021","unstructured":"Hayward SE, Deal A, Cheng C et al (2021) Clinical outcomes and risk factors for COVID-19 among migrant populations in high-income countries: A systematic review (electronic article). J Migr Health 3:100041. doi.org\/10.1016\/j.jmh.2021.100041","journal-title":"J Migr Health"},{"issue":"10286","key":"ref4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(21)00634-6","article-title":"Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform","volume":"397","author":"Mathur R","year":"2021","unstructured":"Mathur R, Rentsch CT, Morton CE et al (2021) Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet 397(10286):1711\u20131724. 10.1016\/S0140-6736(21)00634-6","journal-title":"Lancet"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12889-022-12698-9","article-title":"Structural racism and COVID-19 response: higher risk of exposure drives disparate COVID-19 deaths among Black and Hispanic\/Latinx residents of Illinois, USA","volume":"22","author":"Holden TM","year":"2022","unstructured":"Holden TM, Simon MA, Arnold DT et al (2022) Structural racism and COVID-19 response: higher risk of exposure drives disparate COVID-19 deaths among Black and Hispanic\/Latinx residents of Illinois, USA. BMC Public Health 22(1):312. 10.1186\/s12889-022-12698-9","journal-title":"BMC Public Health"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1007\/s11606-021-07003-0","article-title":"Death toll of COVID-19 on Asian Americans: Disparities revealed","volume":"36","author":"Yan BW","year":"2021","unstructured":"Yan BW, Hwang AL, Ng F et al (2021) Death toll of COVID-19 on Asian Americans: Disparities revealed. J Gen Intern Med 36(11):3545\u20133549. 10.1007\/s11606-021-07003-0","journal-title":"J Gen Intern Med"},{"issue":"12","key":"ref7","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1007\/s11606-020-06264-5","article-title":"Asian-Americans and Pacific Islanders in COVID-19: Emerging disparities amid discrimination","volume":"35","author":"Wang D","year":"2020","unstructured":"Wang D, Gee GC, Bahiru E et al (2020) Asian-Americans and Pacific Islanders in COVID-19: Emerging disparities amid discrimination. J Gen Intern Med 35(12):3685\u20133688. 10.1007\/s11606-020-06264-5","journal-title":"J Gen Intern Med"},{"key":"ref8","unstructured":"Public Health England. Beyond the data: understanding the impact of COVID-19 on BAME groups (2020) Accessed: May 2, 2022. Available at https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/892376\/COVID_stakeholder_engagement_synthesis_beyond_the_data.pdf"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101313","DOI":"10.1016\/j.eclinm.2022.101313","article-title":"Improving Asian American health during the Syndemic of COVID-19 and racism (electronic article)","volume":"45","author":"Saw A","year":"2022","unstructured":"Saw A, Yi SS, \u00d0o\u00e0n LN et al (2022) Improving Asian American health during the Syndemic of COVID-19 and racism (electronic article). EClinicalMedicine 45:101313. doi.org\/10.1016\/j.eclinm.2022.101313","journal-title":"EClinicalMedicine"},{"key":"ref10","unstructured":"National Institute for Health Research. NIHR and UKRI launch call for research on COVID-19 and ethnicity (2020) Accessed: May 2, 2022. Available from: https:\/\/www.nihr.ac.uk\/news\/nihr-and-ukri-launch-call-for-research-on-covid-19-and-ethnicity\/24658"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"100086","DOI":"10.1016\/j.jmh.2022.100086","article-title":"Ethnic\/racial minorities' and migrants' access to COVID-19 vaccines: A systematic review of barriers and facilitators (electronic article)","volume":"5","author":"Abba-Aji M","year":"2022","unstructured":"Abba-Aji M, Stuckler D, Galea S et al (2022) Ethnic\/racial minorities' and migrants' access to COVID-19 vaccines: A systematic review of barriers and facilitators (electronic article). J Migr Health 5:100086. doi.org\/10.1016\/j.jmh.2022.100086","journal-title":"J Migr Health"},{"issue":"18","key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18189904","article-title":"Changing the narrative: Structural barriers and racial and ethnic inequities in COVID-19 vaccination (electronic article)","volume":"18","author":"Njoku A","year":"2021","unstructured":"Njoku A, Joseph M, Felix R (2021) Changing the narrative: Structural barriers and racial and ethnic inequities in COVID-19 vaccination (electronic article). Int J Environ Res Public Health 18(18). 10.3390\/ijerph18189904","journal-title":"Int J Environ Res Public Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.15585\/mmwr.mm7103e1","article-title":"Racial and ethnic disparities in receipt of medications for treatment of COVID-19 \u2014 United States, March 2020\u2013August 2021","volume":"71","author":"Wiltz JL","year":"2022","unstructured":"Wiltz JL, Feehan AK, Molinari NM et al (2022) Racial and ethnic disparities in receipt of medications for treatment of COVID-19 \u2014 United States, March 2020\u2013August 2021. MMWR Morb Mortal Wkly Rep 71:96\u2013102. 10.15585\/mmwr.mm7103e1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"year":"2022","author":"Oliveira JESL","key":"ref14","unstructured":"Oliveira JESL, Gerberi DJ, Cummins NW et al (2022) Representativeness of Racial and Ethnic Groups in COVID-19 Outpatient Trials in the United States. Mayo Clin Proc. ;97(1):184-6"},{"issue":"0 7","key":"ref15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.28575","article-title":"Twenty years post-NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials","volume":"7","author":"Chen MS","year":"2014","unstructured":"Chen MS Jr, Lara PN, Dang JH et al (2014) Twenty years post-NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer 7(0 7):1091\u20131096. 10.1002\/cncr.28575","journal-title":"Cancer"},{"issue":"3","key":"ref16","first-page":"4","article-title":"The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research","volume":"81","author":"Department of Health, Education, and Welfare; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research","year":"2014","unstructured":"Department of Health, Education, and Welfare; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (2014) The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research. J Am Coll Dent 81(3):4\u201313","journal-title":"J Am Coll Dent"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.lana.2022.100252","article-title":"Race\/ethnicity reporting and representation in US clinical trials: A cohort study (electronic article)","volume":"11","author":"Turner BE","year":"2022","unstructured":"Turner BE, Steinberg JR, Weeks BT et al (2022) Race\/ethnicity reporting and representation in US clinical trials: A cohort study (electronic article). Lancet Reg Health Am 11:100252. 10.1016\/j.lana.2022.100252","journal-title":"Lancet Reg Health Am"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"106237","DOI":"10.1016\/j.cct.2020.106237","article-title":"Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications","volume":"101","author":"Fain KM","year":"2021","unstructured":"Fain KM, Nelson JT, Tse T et al (2021) Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications. Contemp Clin Trials (electronic article) 101:106237. 10.1016\/j.cct.2020.106237","journal-title":"Contemp Clin Trials (electronic article)"},{"issue":"3","key":"ref19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/jwh.2010.2469","article-title":"Inclusion, analysis, and reporting of sex and race\/ethnicity in clinical trials: Have we made progress?","volume":"20","author":"Geller SE","year":"2011","unstructured":"Geller SE, Koch A, Pellettieri B et al (2011) Inclusion, analysis, and reporting of sex and race\/ethnicity in clinical trials: Have we made progress? J Womens Health (Larchmt) 20(3):315\u2013320. 10.1089\/jwh.2010.2469","journal-title":"J Womens Health (Larchmt)"},{"key":"ref20","unstructured":"U.S. Department of Health and Human Services. Inclusion of women and minorities in clinical research, Public Health Service Act sec. 492B, 42 U.S.C. sec. 289a-2 (2007) Available from: https:\/\/www.govinfo.gov\/content\/pkg\/USCODE-2011-title42\/pdf\/USCODE-2011-title42-chap6A-subchapIII-partH-sec289a-2.pdf"},{"key":"ref21","unstructured":"National Institutes of Health. Amendment: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research, NOT-OD-18-014 (2017) Available from: https:\/\/grants.nih.gov\/sites\/default\/files\/Valid%20analysis%20CTgov%20guidance%20final_508c.pdf"},{"year":"2022","author":"Momoh O","key":"ref22","unstructured":"Momoh O, Burriss SW, Harry A et al (2022) Inclusion & diversity in clinical trials. Accessed: March 24, Available from: https:\/\/toolbox.eupati.eu\/wp-content\/uploads\/sites\/4\/2020\/11\/EUPATI_Inclusion-and-Diversity-in-Clinical-Trials.pdf"},{"key":"ref23","unstructured":"U.S. Department of Health and Human Services. Enhancing the diversity of clinical trial populations \u2014 eligibility criteria, enrollment practices, and trial designs guidance for industry (2020) Accessed: March 24, 2022. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial"},{"issue":"7","key":"ref24","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.2106\/JBJS.M.00531","article-title":"Lack of diversity in orthopaedic trials conducted in the United States (electronic article)","volume":"96","author":"Somerson JS","year":"2014","unstructured":"Somerson JS, Bhandari M, Vaughan CT et al (2014) Lack of diversity in orthopaedic trials conducted in the United States (electronic article). J Bone Joint Surg Am 96(7):e56. 10.2106\/JBJS.M.00531","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"ref25","first-page":"279","article-title":"A new model for developing and executing culturally appropriate behavior modification clinical trials for African Americans","volume":"13","author":"Ard JD","year":"2003","unstructured":"Ard JD, Carter-Edwards L, Svetkey LP (2003) A new model for developing and executing culturally appropriate behavior modification clinical trials for African Americans. Ethn Dis 13(2):279\u2013285","journal-title":"Ethn Dis"},{"issue":"5","key":"ref26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.janxdis.2012.02.011","article-title":"Minority inclusion in randomized clinical trials of panic disorder","volume":"26","author":"Mendoza DB","year":"2012","unstructured":"Mendoza DB, Williams MT, Chapman LK et al (2012) Minority inclusion in randomized clinical trials of panic disorder. J Anxiety Disord 26(5):574\u2013582. 10.1016\/j.janxdis.2012.02.011","journal-title":"J Anxiety Disord"},{"issue":"2","key":"ref27","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.2105\/AJPH.2013.301706","article-title":"A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders","volume":"104","author":"George S","year":"2014","unstructured":"George S, Duran N, Norris K (2014) A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health 104(2):e16\u2013e31. 10.2105\/AJPH.2013.301706","journal-title":"Am J Public Health"},{"issue":"8","key":"ref28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein TE","year":"2009","unstructured":"Klein TE, Altman RB, Eriksson N et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8):753\u2013764. 10.1056\/NEJMoa0809329","journal-title":"N Engl J Med"},{"issue":"5","key":"ref29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1001\/jamaoncol.2016.0005","article-title":"Intrinsic genomic differences between African American and White patients with clear cell renal cell carcinoma","volume":"2","author":"Krishnan B","year":"2016","unstructured":"Krishnan B, Rose TL, Kardos J et al (2016) Intrinsic genomic differences between African American and White patients with clear cell renal cell carcinoma. JAMA Oncol 2(5):664\u2013667. 10.1001\/jamaoncol.2016.0005","journal-title":"JAMA Oncol"},{"issue":"3","key":"ref30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ng.763","article-title":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia","volume":"43","author":"Yang JJ","year":"2011","unstructured":"Yang JJ, Cheng C, Devidas M et al (2011) Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 43(3):237\u2013241. 10.1038\/ng.763","journal-title":"Nat Genet"},{"issue":"9","key":"ref31","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","article-title":"Enrollment of non-White participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: A systematic review","volume":"98","author":"Onuorah HM","year":"2022","unstructured":"Onuorah HM, Charron O, Meltzer E, Montague A, Crispino A, Largent A et al (2022) Enrollment of non-White participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: A systematic review. Neurology 98(9):e880\u2013e92. 10.1212\/WNL.0000000000013230","journal-title":"Neurology"},{"issue":"9","key":"ref32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1212\/WNL.0000000000013224","article-title":"Non-White participants matter in white matter disease studies: the importance of diversity in multiple sclerosis clinical trials","volume":"98","author":"Hamilton RH","year":"2022","unstructured":"Hamilton RH, Ciccarelli O (2022) Non-White participants matter in white matter disease studies: the importance of diversity in multiple sclerosis clinical trials. Neurology 98(9):345\u2013346. 10.1212\/WNL.0000000000013224","journal-title":"Neurology"},{"issue":"5","key":"ref33","doi-asserted-by":"publisher","first-page":"e218348","DOI":"10.1001\/jamanetworkopen.2021.8348","article-title":"Racial and ethnic disparities in primary open-angle glaucoma clinical trials: A systematic review and meta-analysis (electronic article)","volume":"4","author":"Allison K","year":"2021","unstructured":"Allison K, Patel DG, Greene L (2021) Racial and ethnic disparities in primary open-angle glaucoma clinical trials: A systematic review and meta-analysis (electronic article). JAMA Netw Open 4(5):e218348. 10.1001\/jamanetworkopen.2021.8348","journal-title":"JAMA Netw Open"},{"issue":"4","key":"ref34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.sleh.2019.11.009","article-title":"Reporting results in U.S. clinical trials for obstructive sleep apnea and insomnia: How transparent are they?","volume":"6","author":"He Z","year":"2020","unstructured":"He Z, Wallace DM, Barnes A et al (2020) Reporting results in U.S. clinical trials for obstructive sleep apnea and insomnia: How transparent are they? Sleep Health 6(4):529\u2013533. 10.1016\/j.sleh.2019.11.009","journal-title":"Sleep Health"},{"issue":"7","key":"ref35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1001\/jamaoto.2021.0550","article-title":"Racial\/ethnic and sex representation in US-Based clinical trials of hearing loss management in adults: A systematic review","volume":"147","author":"Pittman CA","year":"2021","unstructured":"Pittman CA, Roura R, Price C et al (2021) Racial\/ethnic and sex representation in US-Based clinical trials of hearing loss management in adults: A systematic review. JAMA Otolaryngol Head Neck Surg 147(7):656\u2013662. 10.1001\/jamaoto.2021.0550","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"ref36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/eat.23699","article-title":"A systematic review of sociodemographic reporting and representation in eating disorder psychotherapy treatment trials in the United States","volume":"55","author":"Burnette CB","year":"2022","unstructured":"Burnette CB, Luzier JL, Weisenmuller CM et al (2022) A systematic review of sociodemographic reporting and representation in eating disorder psychotherapy treatment trials in the United States. Int J Eat Disord 55(4):423\u2013454. 10.1002\/eat.23699","journal-title":"Int J Eat Disord"},{"issue":"1","key":"ref37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14283\/jpad.2021.49","article-title":"Representation of racial and ethnic minority populations in dementia prevention trials: A systematic review","volume":"9","author":"Shaw AR","year":"2022","unstructured":"Shaw AR, Perales-Puchalt J, Johnson E et al (2022) Representation of racial and ethnic minority populations in dementia prevention trials: A systematic review. J Prev Alzheimers Dis 9(1):113\u2013118. 10.14283\/jpad.2021.49","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"ref38","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1038\/s41436-019-0558-2","article-title":"Reporting of race in genome and exome sequencing studies of cancer: A scoping review of the literature","volume":"21","author":"Nugent A","year":"2019","unstructured":"Nugent A, Conatser KR, Turner LL et al (2019) Reporting of race in genome and exome sequencing studies of cancer: A scoping review of the literature. Genet Med 21(12):2676\u20132680. doi.org\/10.1038\/s41436-019-0558-2","journal-title":"Genet Med"},{"issue":"5","key":"ref39","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1377\/hlthaff.2017.1595","article-title":"Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice","volume":"37","author":"Landry LG","year":"2018","unstructured":"Landry LG, Ali N, Williams DR et al (2018) Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. Health Aff (Millwood) 37(5):780\u2013785. 10.1377\/hlthaff.2017.1595","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"ref40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"Checklist and explanation","volume":"169","author":"PRISMA Extension for Scoping Reviews (PRISMA-ScR)","year":"2018","unstructured":"PRISMA Extension for Scoping Reviews (PRISMA-ScR) (2018) Checklist and explanation. Ann Intern Med 169(7):467\u2013473. 10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"year":"2015","author":"Peters M","key":"ref41","unstructured":"Peters M, Godfrey C, McInerney P et al (2015) The Joanna Briggs Institute reviewers' manual 2015: methodology for JBI scoping reviews"},{"issue":"1","key":"ref42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13690-021-00560-0","article-title":"Validation of a search strategy for randomized clinical trials related to periodontitis (electronic article)","volume":"79","author":"Lyrio AO","year":"2021","unstructured":"Lyrio AO, da Cruz SS, Gomes-Filho IS et al (2021) Validation of a search strategy for randomized clinical trials related to periodontitis (electronic article). Arch Public Health 79(1):43. doi.org\/10.1186\/s13690-021-00560-0","journal-title":"Arch Public Health"},{"key":"ref43","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH COVID-19 search strings (2020) Accessed: March 24, 2022. Available from: https:\/\/covid.cadth.ca\/literature-searching-tools\/cadth-covid-19-search-strings\/#covid-19-medline"},{"key":"ref44","unstructured":"World Health Organization Therapeutics and COVID-19: living guideline. Accessed: March 24, 2022. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.4"},{"key":"ref45","unstructured":"US Food and Drug Administration Emergency Use Authorization. Accessed: April 15, 2022. Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#coviddrugs"},{"author":"Mellor L","key":"ref46","unstructured":"Mellor L How to get started with a scoping review. Accessed: March 24, 2022. Available from: https:\/\/www.covidence.org\/blog\/how-to-get-started-with-a-scoping-review\/"},{"issue":"1","key":"ref47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: Towards a methodological framework","volume":"8","author":"Arksey H","year":"2005","unstructured":"Arksey H, O'Malley L (2005) Scoping studies: Towards a methodological framework. Int J Soc Res Methodol 8(1):19\u201332. doi.org\/10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range (electronic article)","volume":"14","author":"Wan X","year":"2014","unstructured":"Wan X, Wang W, Liu J et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range (electronic article). BMC Med Res Methodol 14(1):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"ref49","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4269\/ajtmh.21-0606","article-title":"Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial","volume":"106","author":"Abd-Elsalam S","year":"2021","unstructured":"Abd-Elsalam S, Salama M, Soliman S et al (2021) Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial. Am J Trop Med Hyg 106(3):886\u2013890. 10.4269\/ajtmh.21-0606","journal-title":"Am J Trop Med Hyg"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.17.21258639","author":"Fischer W","year":"2021","unstructured":"Fischer W, Eron JJ, Holman W et al (2021) Molnupiravir, an Oral Antiviral Treatment for COVID-19 (electronic preprint). medRxiv. ;2021.06.17.21258639. 10.1101\/2021.06.17.21258639"},{"issue":"Suppl 1","key":"ref51","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.4103\/ija.IJA_149_21","article-title":"Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study","volume":"65","author":"Mahajan L","year":"2021","unstructured":"Mahajan L, Singh AP, Gifty (2021) Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. Indian J Anaesth 65(Suppl 1):S41\u2013s6. 10.4103\/ija.IJA_149_21","journal-title":"Indian J Anaesth"},{"issue":"11","key":"ref52","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: A randomized clinical trial","volume":"47","author":"Rosas IO","year":"2021","unstructured":"Rosas IO, Diaz G, Gottlieb RL et al (2021) Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: A randomized clinical trial. Intensive Care Med 47(11):1258\u20131270. 10.1007\/s00134-021-06507-x","journal-title":"Intensive Care Med"},{"issue":"2","key":"ref53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader F","year":"2022","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M et al (2022) Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 22(2):209\u2013221. 10.1016\/S1473-3099(21)00485-0","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"ref54","doi-asserted-by":"publisher","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial","volume":"194","author":"Ali K","year":"2022","unstructured":"Ali K, Azher T, Baqi M et al (2022) Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: A randomized controlled trial. CMAJ 194(7):E242\u2013E51. 10.1503\/cmaj.211698","journal-title":"CMAJ"},{"issue":"9","key":"ref55","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.7326\/M21-0653","article-title":"Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: A randomized trial","volume":"174","author":"Barratt-Due A","year":"2021","unstructured":"Barratt-Due A, Olsen IC, Nezvalova-Henriksen K et al (2021) Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: A randomized trial. Ann Intern Med 174(9):1261\u20131269. 10.7326\/M21-0653","journal-title":"Ann Intern Med"},{"issue":"4","key":"ref56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely EW","year":"2022","unstructured":"Ely EW, Ramanan AV, Kartman CE et al (2022) Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial. Lancet Respir Med 10(4):327\u2013336. 10.1016\/S2213-2600(22)00006-6","journal-title":"Lancet Respir Med"},{"issue":"628","key":"ref57","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus (electronic article)","volume":"14","author":"Fischer WA","year":"2022","unstructured":"Fischer WA 2nd, Eron JJ Jr., Holman W et al (2022) A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus (electronic article). Sci Transl Med 14(628):eabl7430. 10.1126\/scitranslmed.abl7430","journal-title":"Sci Transl Med"},{"issue":"6","key":"ref58","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal A","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB et al (2022) Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. New Engl J Med 386(6):509\u2013520. 10.1056\/NEJMoa2116044","journal-title":"New Engl J Med"},{"issue":"9","key":"ref59","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil AC","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK et al (2021) Baricitinib plus remdesivir for hospitalized adults with COVID-19. New Engl J Med 384(9):795\u2013807. 10.1056\/NEJMoa2031994","journal-title":"New Engl J Med"},{"issue":"12","key":"ref60","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi VC","year":"2021","unstructured":"Marconi VC, Ramanan AV, de Bono S et al (2021) Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 9(12):1407\u20131418. 10.1016\/S2213-2600(21)00331-3","journal-title":"Lancet Respir Med"},{"issue":"11","key":"ref61","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial","volume":"324","author":"Spinner CD","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ et al (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA 324(11):1048\u20131057. 10.1001\/jama.2020.16349","journal-title":"JAMA"},{"issue":"10236","key":"ref62","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395(10236):1569\u20131578. 10.1016\/S0140-6736(20)31022-9","journal-title":"Lancet"},{"issue":"10339","key":"ref63","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","author":"WHO Solidarity Trial Consortium","year":"2022","unstructured":"WHO Solidarity Trial Consortium (2022) Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 399(10339):1941\u20131953. 10.1016\/S0140-6736(22)00519-0","journal-title":"Lancet"},{"issue":"4","key":"ref64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb RL","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R et al (2022) Early remdesivir to prevent progression to severe COVID-19 in outpatients. New Engl J Med 386(4):305\u2013315. 10.1056\/NEJMoa2116846","journal-title":"New Engl J Med"},{"issue":"19","key":"ref65","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in patients with severe COVID-19","volume":"383","author":"Goldman JD","year":"2020","unstructured":"Goldman JD, Lye DCB, Hui DS et al (2020) Remdesivir for 5 or 10 Days in patients with severe COVID-19. New Engl J Med 383(19):1827\u20131837. 10.1056\/NEJMoa2015301","journal-title":"New Engl J Med"},{"issue":"19","key":"ref66","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 \u2014 Final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of COVID-19 \u2014 Final report. New Engl J Med 383(19):1813\u20131826. 10.1056\/NEJMoa2007764","journal-title":"New Engl J Med"},{"issue":"5","key":"ref67","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1002\/jmv.26897","article-title":"Estimation of undetected symptomatic and asymptomatic cases of COVID-19 infection and prediction of its spread in the USA","volume":"93","author":"Mahajan A","year":"2021","unstructured":"Mahajan A, Solanki R, Sivadas N (2021) Estimation of undetected symptomatic and asymptomatic cases of COVID-19 infection and prediction of its spread in the USA. J Med Virol 93(5):3202\u20133210. 10.1002\/jmv.26897","journal-title":"J Med Virol"},{"issue":"3","key":"ref68","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/1740774517697919","article-title":"Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization","volume":"14","author":"Peterson RL","year":"2017","unstructured":"Peterson RL, Vock DM, Powers JH et al (2017) Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. Clin Trials 14(3):264\u2013276. 10.1177\/1740774517697919","journal-title":"Clin Trials"},{"issue":"4","key":"ref69","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.36076\/ppj.2020\/23\/S381","article-title":"Value and Validity of Coronavirus Antibody Testing","volume":"23","author":"Mahajan A","year":"2020","unstructured":"Mahajan A, Manchikanti L (2020) Value and Validity of Coronavirus Antibody Testing. Pain Physician 23(4):S381\u2013S90","journal-title":"Pain Physician"},{"year":"2022","author":"Pranic SM","key":"ref70","unstructured":"Pranic SM (2022) Protocol of a scoping review of COVID-19 randomized controlled drug and biologicals trials reporting participant race. Available from: http:\/\/www.osf.io\/3dx4f"},{"issue":"5","key":"ref71","doi-asserted-by":"publisher","first-page":"e0250735","DOI":"10.1371\/journal.pone.0250735","article-title":"Race and ethnicity do not impact eligibility for remdesivir: A single-center experience","volume":"16","author":"Pischel L","year":"2021","unstructured":"Pischel L, Walelo M, Benson J et al (2021) Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PLoS ONE 16(5):e0250735. 10.1371\/journal.pone.0250735","journal-title":"PLoS ONE"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijsu.2020.04.001","article-title":"Evidence based management guideline for the COVID-19 pandemic - Review article","volume":"77","author":"Nicola M","year":"2020","unstructured":"Nicola M, O'Neill N, Sohrabi C et al (2020) Evidence based management guideline for the COVID-19 pandemic - Review article. Int J Surg 77:206\u2013216. 10.1016\/j.ijsu.2020.04.001","journal-title":"Int J Surg"},{"issue":"3","key":"ref73","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: Understanding mistrust about research participation","volume":"21","author":"Scharff DP","year":"2010","unstructured":"Scharff DP, Mathews KJ, Jackson P et al (2010) More than Tuskegee: Understanding mistrust about research participation. J Health Care Poor Underserved 21(3):879\u2013897. 10.1353\/hpu.0.0323","journal-title":"J Health Care Poor Underserved"},{"issue":"6","key":"ref74","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2105\/AJPH.2021.306273","article-title":"Emergency use authorizations (EUAs) versus FDA approval: Implications for COVID-19 and public health","volume":"111","author":"Zuckerman DM","year":"2021","unstructured":"Zuckerman DM (2021) Emergency use authorizations (EUAs) versus FDA approval: Implications for COVID-19 and public health. Am J Public Health 111(6):1065\u20131069. 10.2105\/AJPH.2021.306273","journal-title":"Am J Public Health"},{"issue":"3","key":"ref75","doi-asserted-by":"publisher","first-page":"e213071","DOI":"10.1001\/jamanetworkopen.2021.3071","article-title":"Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19 (electronic article)","volume":"4","author":"Garibaldi BT","year":"2021","unstructured":"Garibaldi BT, Wang K, Robinson ML et al (2021) Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19 (electronic article). JAMA Netw Open 4(3):e213071\u2013e. 10.1001\/jamanetworkopen.2021.3071","journal-title":"JAMA Netw Open"},{"issue":"10","key":"ref76","doi-asserted-by":"crossref","first-page":"e2130479","DOI":"10.1001\/jamanetworkopen.2021.30479","article-title":"Racial and ethnic disparities in rates of COVID-19-associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021 (electronic article)","volume":"4","author":"Acosta AM","year":"2021","unstructured":"Acosta AM, Garg S, Pham H et al (2021) Racial and ethnic disparities in rates of COVID-19-associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021 (electronic article). JAMA Netw Open 4(10):e2130479","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ref77","doi-asserted-by":"publisher","first-page":"429","DOI":"10.18865\/ed.30.3.429","article-title":"Impact of COVID-19 on clinical research and inclusion of diverse populations","volume":"30","author":"Lackland DT","year":"2020","unstructured":"Lackland DT, Sims-Robinson C, Jones Buie JN et al (2020) Impact of COVID-19 on clinical research and inclusion of diverse populations. Ethn Dis 30(3):429\u2013432. 10.18865\/ed.30.3.429","journal-title":"Ethn Dis"},{"year":"2022","author":"Lancet","key":"ref78","unstructured":"Lancet (2022) Information for authors. Accessed September 28, 2022. Available from: https:\/\/www.thelancet.com\/pb\/assets\/raw\/Lancet\/authors\/tl-info-for-authors.pdf"},{"key":"ref79","unstructured":"Annals of Internal Medicine. Information for authors. Accessed September 28 (2022) Available from: https:\/\/www.acpjournals.org\/pb-assets\/pdf\/AnnalsAuthorInfo-1656457118343.pdf"},{"issue":"1","key":"ref80","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1017\/cts.2021.797","article-title":"Development of a multi-component intervention to promote participation of Black and Latinx individuals in biomedical research","volume":"5","author":"Danila MI","year":"2021","unstructured":"Danila MI, Allison JJ, Goins KV, Chiriboga G, Fischer M, Puliafico M et al (2021) Development of a multi-component intervention to promote participation of Black and Latinx individuals in biomedical research. J Clin Transl Sci 5(1):e134. 10.1017\/cts.2021.797","journal-title":"J Clin Transl Sci"},{"issue":"1","key":"ref81","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12874-022-01708-4","article-title":"What influences communication about retention in randomised trials: a multi-trial, theory-based analysis exploring trial staff perspectives","volume":"22","author":"Coffey T","year":"2022","unstructured":"Coffey T, Duncan E, Morgan H et al (2022) What influences communication about retention in randomised trials: a multi-trial, theory-based analysis exploring trial staff perspectives. BMC Med Res Methodol (electronic article) 22(1):231. 10.1186\/s12874-022-01708-4","journal-title":"BMC Med Res Methodol (electronic article)"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.publhealth.27.021405.102113","article-title":"Effective recruitment and retention of minority research participants","volume":"27","author":"Yancey AK","year":"2006","unstructured":"Yancey AK, Ortega AN, Kumanyika SK (2006) Effective recruitment and retention of minority research participants. Annu Rev Public Health 27:1\u201328. 10.1146\/annurev.publhealth.27.021405.102113","journal-title":"Annu Rev Public Health"},{"key":"ref83","doi-asserted-by":"crossref","DOI":"10.1093\/epirev\/mxac007","article-title":"Inclusionary trials: A review of lessons not learned","author":"Adkins-Jackson PB","year":"2022","unstructured":"Adkins-Jackson PB, Burke NJ, Espinosa PR, Ison JM, Goold SD, Rosas LG et al (2022) Inclusionary trials: A review of lessons not learned. Epidemiol Rev. mxac007","journal-title":"Epidemiol Rev"},{"issue":"3","key":"ref84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jama.2019.19329","article-title":"Disparities Research, Disparities Researchers, and Health Equity","volume":"323","author":"Carnethon MR","year":"2020","unstructured":"Carnethon MR, Kershaw KN, Kandula NR (2020) Disparities Research, Disparities Researchers, and Health Equity. JAMA 323(3):211\u2013212. 10.1001\/jama.2019.19329","journal-title":"JAMA"},{"key":"ref85","unstructured":"National Institutes of Health. Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Funded Research. Accessed July 1 (2023) Available from: https:\/\/commonfund.nih.gov\/first\/fundedresearch"},{"issue":"3","key":"ref86","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/aje\/kwac146","article-title":"Conceptualization, Operationalization, and Utilization of Race and Ethnicity in Major Epidemiology Journals, 1995\u20132018: A Systematic Review","volume":"192","author":"Martinez RAM","year":"2023","unstructured":"Martinez RAM, Andrabi N, Goodwin AN, Wilbur RE, Smith NR, Zivich PN (2023) Conceptualization, Operationalization, and Utilization of Race and Ethnicity in Major Epidemiology Journals, 1995\u20132018: A Systematic Review. Am J Epidemiol 192(3):483\u2013496. 10.1093\/aje\/kwac146","journal-title":"Am J Epidemiol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4092537\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4092537\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:32:39Z","timestamp":1710441159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4092537\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":86,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4092537\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,3,14]]},"subtype":"preprint"}}